Based on the bioinformatic analysis (Figure 1), we chose two breast cancer cell lines, including TNBC-derived MDA-MB-231 and ER+-derived MCF-7 cells, to explore the potential anti-proliferative effects of these hERG activators using the CCK-8 assay. Here, ESR1 is linked to breast carcinoma.